Cargando…
Simvastatin Inhibits Endometrial Cancer Malignant Behaviors by Suppressing RAS/Mitogen-Activated Protein Kinase (MAPK) Pathway-Mediated Reactive Oxygen Species (ROS) and Ferroptosis
This paper was designed to explore the function of simvastatin as a chemotherapeutic drug on the endometrial cancer (EC) cell proliferation, invasion, and ferroptosis. Firstly, a number of in vitro experiments were conducted to determine the impact of different treatments of simvastatin on the Ishik...
Autores principales: | Zhou, Dan, Wu, Qiuhua, Qiu, Huajuan, Li, Mi, Ji, Yanqin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586725/ https://www.ncbi.nlm.nih.gov/pubmed/36276874 http://dx.doi.org/10.1155/2022/6177477 |
Ejemplares similares
-
Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways?
por: Son, Yong, et al.
Publicado: (2011) -
The Kinase Activity-deficient Isoform of the Protein Araf Antagonizes Ras/Mitogen-activated Protein Kinase (Ras/MAPK) Signaling in the Zebrafish Embryo
por: Xiong, Cong, et al.
Publicado: (2015) -
Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation
por: Lee, Ye-Ming, et al.
Publicado: (2010) -
Ras Mitogen-activated Protein Kinase Signaling and Kinase Suppressor of Ras as Therapeutic Targets for Hepatocellular Carcinoma
por: Moon, Hyuk, et al.
Publicado: (2021) -
Amentoflavone promotes ferroptosis by regulating reactive oxygen species (ROS) /5’AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) to inhibit the malignant progression of endometrial carcinoma cells
por: Sun, Qi, et al.
Publicado: (2022)